HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $55 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Zentalis Pharma (NASDAQ:ZNTL) and maintained a $55 price target.
August 10, 2023 | 10:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zentalis Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $55.
The reiteration of a 'Buy' rating and maintained price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. This could potentially lead to increased investor confidence and a short-term increase in Zentalis Pharma's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100